Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2011

View Archived Issues

NK-012 shows promising activity in phase II trial in sensitive relapsed SCLC

MORAb-004 is active in first-in-human study

Allergan patents novel lysophospholipid S1P1 receptor modulators

New beta-secretase 2 inhibitors for diabetes patented by Roche

Novel AMPK activators synthesized

Compugen validates second candidate based on CD28/B7 costimulatory family

Randox launches automated H-FABP assay

SK Chemicals' new 11-beta-HSD1 inhibitor SKI-2852 is active in models of diabetes

RG-7112 advances through clinical development for cancer

Preliminary phase I data suggest safety/activity of RO-4987655 in advanced/metastatic solid tumors

PSN-821 reduces energy intake in patients with obesity and type 2 diabetes

Novartis patents new cytochrome P450 inhibitors

Novel arachidonic acid analogues prepared by Cytometix for use as analgesics

CHMP adopts positive opinion on Buccolam

Alzheimer's Drug Discovery Foundation supports Axxam research

Nile Therapeutics advances phase I trial of cenderitide for heart failure

Amgen obtains positive CHMP opinion on Vectibix after reexamination

Mimetogen reports promising phase II data on MIM-D3 in dry eye syndrome

EMA accepts tesamorelin MAA for review

Immunomedics receives third milestone payment related to veltuzumab development

Apeiron Biologics enters research alliance for neuroblastoma therapy CH-14.18

Banzel approved in Canada for seizures associated with Lennox-Gastaut syndrome

Jevtana/prednisone combination approved in Canada for prostate cancer

Evotec and Roche collaborate on protein-activity based biomarkers for use in oncology

ERYtech completes enrollment in phase I Graspa trial in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...